The trouble with Ostarine: Jimmy Wallhead’s
16th March 2018
A decision has been issued under the Tennis Anti-Doping Programme (the “Programme”) that Camilla Bossi has committed an Anti-Doping Rule Violation under Article 2.1. That decision imposed a period of ineligibility of six months, commencing on 27 March 2019.
Ms. Bossi, a 16-year-old player from Brazil, provided a urine sample on 27 March 2019 in association with her participation in the WTT W25 Campinas held in Campinas, Brazil from 25 March to 31 March 2019 (the “Event”). That sample was sent to the World Anti-Doping Agency (“WADA”) accredited laboratory in Montreal, Canada for analysis, and was found to contain Enobosarm (SARM S-22), which is a Non-Specified substance under category S1 (Anabolic Agents) of the 2019 WADA Prohibited List, and therefore is also prohibited under the Programme.
Ms. Bossi was charged with an Anti-Doping Rule Violation under Article 2.1 of the Programme (presence of a Prohibited Substance in a Player’s Sample) and was provisionally suspended on 17 May 2019. This is Ms. Bossi’s first Anti-Doping Rule Violation. The decision determines that: (1) Ms. Bossi has committed a violation of the Programme; (2) she must serve a period of ineligibility of six months; and (3) that period of ineligibility is back-dated to start on 27 March 2019 (the date of sample collection), and so ending at midnight on 26 September 2019. In accordance with Programme articles 9.1 and 10.8, all ranking points and prize money obtained by Ms. Bossi at the Event and subsequent events are disqualified.
• This media release was published by the International Tennis Federation (ITF) on 11 November 2019. Click here for the original, and click here for the Full Decision.
International Boxing Association (AIBA) has retained McLaren Sport Solution (MGSS), led by Professor Richard McLaren,...
FIBA has received since June 10 through the New York Times and Human Rights Watch...